[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100526566":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":31,"responsibleParty":65,"collaborators":20,"id":67,"slug":20,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":68,"sex":73,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":20,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":88,"overallStatus":34,"whyStopped":20,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"Centre Hospitalier Universitaire de Nice","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"deucravacitinib treatment","EXPERIMENTAL","challenge-dechallenge -rechallenge design",[13],"Drug: deucravacitinib",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","deucravacitinib","treatment by deucravacitinib in two phases of challenge",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Christine Chiaverini","PRINCIPAL_INVESTIGATOR",[26],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},"christine chiaverini","CONTACT","04.92.03.47.02","chiaverini.c@chu-nice.fr",[32,50],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"CHU de Nice","RECRUITING","Nice","CHU de NICE","06003","France",{"type":40,"coordinates":41},"Point",[42,43],7.26608,43.70313,{"lat":43,"lon":42},[46,48],{"name":20,"role":28,"phone":47,"phoneExt":20,"email":20},"0492034702",{"name":49,"role":24,"phone":20,"phoneExt":20,"email":20},"Christine CHIAVERINI",{"facility":51,"status":34,"city":52,"state":38,"zip":53,"country":38,"cosmosGeoPoint":54,"geoPoint":58,"contacts":59},"APHP St Louis","Paris","75010",{"type":40,"coordinates":55},[56,57],2.3488,48.85341,{"lat":57,"lon":56},[60,64],{"name":61,"role":28,"phone":62,"phoneExt":20,"email":63},"Emmanuelle BOURRAT, Doctor","01 42 49 45 41","marioncauseret@yahoo.fr",{"name":61,"role":24,"phone":20,"phoneExt":20,"email":20},{"type":66,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100526566",false,"NCT06136403","A 44-week Monocentric Open Study Assessing the Efficacy and Safety of Deucravacitinib in Adults With Inflammatory Genodermatoses","GENEPID","Inclusion Criteria:\n\n* Subject has congenital skin fragility with skin and\u002For mucosal blisters, a clinical phenotype of EBS-sev and a laboratory confirmed diagnosis of EBS by KRT5 and\u002For 14 mutation (autosomal only) OR a clinical phenotype of inflammatory ichthyosis (IC) including keratinopathic ichthyosis due to KRT1\u002F10 mutation, ECI with identified genetic mutations (TGM5, NIPAL4, ABCA12, etc…).\n* Subject has at least a mean daily number of 4 new blisters (EBS-sev) OR an ISS \\> 50\u002F128.\n\n  * Subject agrees not to use any topical therapies other than the investigator approved.\n\nExclusion Criteria:\n\n* Subjects with another form of ICI ie Netherton syndrome, Kid syndrome etc.\n* Infectious\u002FImmune-related Exclusions\n* Medical History and Concurrent Diseases","ALL","18 Years","99 Years",{"count":77,"type":78},10,"ESTIMATED","INTERVENTIONAL",[81],"PHASE2","The goal of this clinical trial is to learn about deucravacitinib treatment in adults with inflammatory epidermal genodermatoses . The main question it aims to answer are: describe efficacity and safety of this treatment.\n\nParticipants will take treatments and have to use bullets during the study period.",[84,85,86,87],"Epidermolysis Bullosa Simplex","Ichthyosis","Genodermatosis","Inflammatory Congenital Ichthyoses",[17],"2025-07-31",{"date":91,"type":92},"2025-08-05","ACTUAL",{"date":94,"type":92},"2024-03-18",{"date":96,"type":78},"2026-10-12",{"name":5,"class":6},2]